Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 5—May 2022
Research

Effectiveness of BNT162b2 Vaccine Booster against SARS-CoV-2 Infection and Breakthrough Complications, Israel

Aharona Glatman-FreedmanComments to Author , Michal Bromberg, Yael Hershkovitz, Hanna Sefty, Zalman Kaufman, Rita Dichtiar, and Lital Keinan-Boker
Author affiliations: Tel Aviv University School of Public Health, Tel Aviv, Israel (A. Glatman-Freedman, M. Bromberg); Israel Center for Disease Control, Ministry of Health, Ramat Gan, Israel (A. Glatman-Freedman, M. Bromberg, Y. Hershkovitz, H. Sefty, Z. Kaufman, R. Dichtiar, L. Keinan-Boker); Haifa University School of Public Health, Haifa, Israel (L. Keinan-Boker)

Main Article

Table 3

Rate reduction of deaths among SARS-CoV-2–positive persons who received the BNT162b2 COVID-19 vaccine booster dose, Israel*

Age group, y Time of first positive
SARS-CoV-2 PCR test after index date, wk
Unvaccinated SARS-CoV-2–positive persons
Vaccinated SARS-CoV-2–positive persons
Adjusted 1 – IRR, % (95% CI)†
Deaths Total Deaths Total
16–59 2 45 22,545 0 1,343 100
3 36 18,232 0 455 100
4 27 12,962 0 293 100
5 17 8,555 0 210 100
6 11 5,531 0 138 100
7 6 3,573 0 131 100
8 5 2,626 0 83 100
9 4 2,013 0 54 100
10 3 1,714 0 57 100
11 3 1,401 0 66 100
12 3 1,385 0 90 100
13 2 1,442 0 118 100
14 1 1,569 0 154 100
15 1 2,145 0 351 100
16 1 4,088 0 884 100

2–16 combined
72
41,135

0
4,427
100
>60 2 243 1,985 31 1,314 81.9 (70.4–88.9)
3 246 2,200 13 464 76.0 (55.3–87.2)
4 226 2,160 13 375 68.1 (49.6–79.8)
5 229 2,164 11 319 68.7 (42.7–82.9)
6 201 2,033 7 296 76.5 (55.9–87.4)
7 166 1,724 8 271 70.5 (29.4–87.7)
8 122 1,276 8 221 63.1 (29.4–80.7)
9 89 869 2 147 87.6 (53.7–96.7)
10 59 577 5 86 49.1 (−44.3 to 82.1)
11 30 376 0 63 100.0
12 19 258 1 44 67.7 (−189.8 to 96.4)
13 19 208 1 52 78.7 (−89.9 to 97.6)
14 22 183 1 49 85.0 (8.5–97.5)
15 21 170 1 47 85.3 (−21.3 to 98.2)
16 17 162 0 44 100.0
17 11 151 1 56 74.6 (−225.9 to 98.0)
18 10 147 0 69 100.0
19 7 184 2 125 56.5 (−144.3 to 92.3)
20 8 305 3 432 70.7 (−2.7 to 91.7)
2–20 combined 686 6,673 108 4,474 77.1 (71.2–81.8)

*COVID-19, coronavirus disease; IRR, incidence rate ratio; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. †Adjusted for sex and epidemiologic week.

Main Article

Page created: March 18, 2022
Page updated: April 19, 2022
Page reviewed: April 19, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external